Dr. Reddy’s Laboratories, a leading Indian pharmaceutical company, has partnered with Pharmazz Inc., a US-based clinical-stage pharmaceutical company, to introduce the life-saving drug Centhaquine, now marketed as Lyfaquin, in the Indian market. This collaboration aims to address the urgent need for an effective treatment for hypovolemic shock in India.
Hypovolemic shock is a critical condition caused by severe blood or fluid loss, leading to a significant decrease in blood volume and inadequate tissue perfusion. It can occur due to various reasons such as trauma, surgery, gastrointestinal bleeding, or severe dehydration. Immediate medical intervention is crucial to prevent organ failure and death.
Centhaquine, a drug developed by Pharmazz Inc., has shown promising results in the management of hypovolemic shock. It acts by increasing the blood pressure and restoring tissue perfusion, thereby preventing organ damage and improving patient outcomes.
Dr. Reddy’s Laboratories recognized the urgent need for a reliable treatment for hypovolemic shock in India and identified Centhaquine as a potential solution. By partnering with Pharmazz Inc., they aim to bring this life-saving drug to Indian patients and healthcare providers.
Under the collaboration, Dr. Reddy’s will have the exclusive right to distribute and market Centhaquine in India. The company will leverage its strong marketing and distribution network to ensure the availability of the drug across the country. Pharmazz Inc. will provide technical and regulatory support for the commercialization of Lyfaquin in the Indian market.
The partnership between Dr. Reddy’s Laboratories and Pharmazz Inc. is a significant step towards addressing the unmet medical needs in India. It highlights the importance of collaborations between domestic and international pharmaceutical companies to improve access to life-saving medications.
India has a high burden of hypovolemic shock cases, particularly in rural areas with limited healthcare infrastructure. The availability of Centhaquine, now marketed as Lyfaquin, will provide an effective treatment option for healthcare providers and help save lives.
Dr. Anil Namboodiripad, Senior Vice President of Dr. Reddy’s Laboratories, expressed his optimism about the partnership, stating, ‘We are delighted to partner with Pharmazz Inc. to bring this innovative drug to India. We believe Centhaquine has the potential to revolutionize the management of hypovolemic shock and improve patient outcomes. This collaboration aligns with our mission to provide affordable and quality healthcare solutions to patients across the country.’
Dr. Nawab Shafi Ul Mulk, Chairman and CEO of Pharmazz Inc., also shared his enthusiasm, saying, ‘We are excited to collaborate with Dr. Reddy’s Laboratories and bring Centhaquine to India, a market with a high need for an effective treatment for hypovolemic shock. Together, we aim to make a meaningful difference in the lives of patients and healthcare providers.’
The partnership between Dr. Reddy’s Laboratories and Pharmazz Inc. is expected to have a significant impact on the management of hypovolemic shock in India. It represents a major step towards improving patient outcomes and reducing the mortality associated with this critical condition.
